In addition, we used GPX4 targeting inhibitor RSL3 to reduce the protein level of GPX4 and promote AML cell death by inducing ferroptosis, indicating that GPX4 is a potential target for AML treatment. This evidence concerns the gene GPX4 and acute myeloid leukemia.